Europe News and Press release service
About Us | Contact Us

Europe News Headlines and Press Release Distribution

Home | Europe News | Press Release Distribution
Unlimited Press Release Distribution

Press release distribution service


News Media




Aftonbladet
Bild.de
BBC
Corriere della Sera
euronews
Financial Times
France24
De Telegraaf
DeutchNews.nl
Daily Mail
Daily & Sunday Expresss
Daily Star
Kronen Zeitung
Le Figaro
Le Monde
Le Parisien
Moskovskij Komsomolets
Ouest France
Repubblica.it
Ukraine.Com
Yahoo Europe
ZAMAN

Europe News and Press Release Distribution

Global Report Of Parkinson’s Treatment Market Size, Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

(EuropeNewsWire.Net, May 16, 2018 ) Known more about Parkinson disease, symptoms and treatment
Parkinsonís Treatment Market: Parkinson disease is a chronic, progressive neurodegenerative disorder that is characterized by tremors, rigidity, postural instability and bradykinesia (slow movement) with non-motor skills such sleep disturbances, in cognition, mood disturbance and autonomic dysfunction are also included. The disease is caused due to degeneration of the dopamine-producing cells of the substantia nigra. It is a slow-degenerative disorder which cannot be cured with poor life quality and increases disability.

A sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-parkinsons-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

Recent advances in the way of the treatment of Parkinsonís disease with combination or multiple medicines and therapies in order to prolong the action of the continuous stimulation of dopaminergic drugs, devices approval, etc. will help slow the degeneration of Parkinsonís diseases treatment globally. Factors such as an increase in older population, treatment affordability, an increase in the number of patients globally will help the market grow for Parkinson disease treatment. On the other hand, patent expiration, the rise in competitive drugs, and extensive unmet supply of the drug are some factors which can hamper the market growth of Parkinsonís disease treatment. The global Parkinsonís Treatment Market can be classified on the basis of drug class, treatment, end user, and geography.

To view TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-parkinsons-treatment-market/#ulp-c654SbFYO64MsOhu

1. Drug class
ē Monoamine Oxidase Inhibitors (MAO)
ē Dopamine Precursors
ē Catechol-o-methyltransferase Inhibitors (COMT)
ē Peripheral Decarboxylase Inhibitors
ē Others (Anticholinergics, Antihistaminic)

2. End-users
Hospital Pharmacies, online Pharmacies, and retail pharmacies
And lastly, it is divided on the basis of geographical regions-North America, Asia-Pacific, Europe, and the Middle East and Africa.

North America holds the first place in the global market for the Parkinsonís disease treatment due to a high incidence of the disease, and good reimbursement policies. According to the Parkinsonís disease Foundation, approximately 60,000 Americans are diagnosed with Parkinsonís disease every year. On the other hand, Europe holds the second place due to its share in the R &D investment and act as major players in the market. Some of the key players in the Parkinsonís treatment market are Salix Pharmaceuticals (US), GlaxoSmithKline (US), Wockhardt Limited (India), Impax Laboratories, Inc., (US), Cipla Inc. (India), Apotex Inc. (Canada), etc. are some names. In 2015 USFDA approved RYTARY, an extended-release oral capsule combination of Carbidopa and Levodopa of Impax Laboratories to treat Parkinsonís disease.

To view TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-parkinsons-treatment-market/#ulp-14mlyhjMGhVjZqa3

Parkinson disease is essentially treated with known and trusted medicines such as dopamine agonists and Levodopa, hence generic drugs still dominate the market. Newer technologies are making their way into the market to offer better quality treatment compared to conventional therapies. Drug manufacturers are accepting more options alongside the Levodopa therapy, therapy such as new product launches and collaborative agreements have been adopted so far. For e.g. Neuropore Therapies Inc. have collaborated with UCB S.A. for drug name NPT200-11, for the treatment of Parkinsonís disease.


Get access to full summary @https://www.precisionbusinessinsights.com/market-reports/global-parkinsons-treatment-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,
Kemp House,
152 Ė 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @https://www.precisionbusinessinsights.com

Precision Business Insights

Satya Satya

+1-866-598-1553

satya@pbigp.com

Source: EmailWire.Com
Europe News by Regions
  • Austria
  • Britain
  • Czech & Slovakia
  • Denmark
  • Eastern Europe
  • France
  • Finland
  • Germany
  • Greece
  • Hungary
  • Italy
  • London
  • Poland
  • Portugal
  • The Netherlands
  • Turkey
  • Russia
  • Spain
  • 
    


    
    
    
    

    Europe Resource Center
    We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:

    Governing
    Point of Beginning
    Overall Labor Effectiveness (OLE) Achieving a Highly Effective Workforce

    No credit cards, coupons, or promo codes required. Try it today!

    Press release service

    EuropeNewswire.net is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

    For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com.
    Copyright 2008 GroupWeb Media LLC
    GroupWeb Media Network

    Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
    | i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
    EuropeNewswire.net ô - Newswire and Press Release service of GroupWeb Media LLC